JP2019501687A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501687A5
JP2019501687A5 JP2018525783A JP2018525783A JP2019501687A5 JP 2019501687 A5 JP2019501687 A5 JP 2019501687A5 JP 2018525783 A JP2018525783 A JP 2018525783A JP 2018525783 A JP2018525783 A JP 2018525783A JP 2019501687 A5 JP2019501687 A5 JP 2019501687A5
Authority
JP
Japan
Prior art keywords
syringe
prefilled syringe
prefilled
vegf
silicone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018525783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501687A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/078136 external-priority patent/WO2017085253A1/en
Publication of JP2019501687A publication Critical patent/JP2019501687A/ja
Publication of JP2019501687A5 publication Critical patent/JP2019501687A5/ja
Priority to JP2022144630A priority Critical patent/JP2022177129A/ja
Pending legal-status Critical Current

Links

JP2018525783A 2015-11-18 2016-11-18 Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ Pending JP2019501687A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022144630A JP2022177129A (ja) 2015-11-18 2022-09-12 Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15195177 2015-11-18
EP15195177.9 2015-11-18
PCT/EP2016/078136 WO2017085253A1 (en) 2015-11-18 2016-11-18 Pre-filled plastic syringe containing a vegf antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022144630A Division JP2022177129A (ja) 2015-11-18 2022-09-12 Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ

Publications (2)

Publication Number Publication Date
JP2019501687A JP2019501687A (ja) 2019-01-24
JP2019501687A5 true JP2019501687A5 (enExample) 2020-01-09

Family

ID=54608352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018525783A Pending JP2019501687A (ja) 2015-11-18 2016-11-18 Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ
JP2022144630A Pending JP2022177129A (ja) 2015-11-18 2022-09-12 Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022144630A Pending JP2022177129A (ja) 2015-11-18 2022-09-12 Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ

Country Status (12)

Country Link
US (3) US20180326126A1 (enExample)
EP (1) EP3377151A1 (enExample)
JP (2) JP2019501687A (enExample)
KR (1) KR20180083377A (enExample)
CN (1) CN108290004A (enExample)
AU (1) AU2016356047B2 (enExample)
BR (1) BR112018010005A2 (enExample)
CA (1) CA3005692A1 (enExample)
MX (1) MX2018006171A (enExample)
RU (1) RU2018121813A (enExample)
WO (1) WO2017085253A1 (enExample)
ZA (1) ZA201802922B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US10576128B2 (en) 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
MX2020006177A (es) 2017-12-13 2020-09-03 Regeneron Pharma Dispositivos y metodos para administracion exacta de dosis.
WO2019136163A1 (en) 2018-01-03 2019-07-11 Irenix Medical, Inc. Therapeutic agent delivery devices having integrated pain mitigation, and methods for using the same
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
KR102467349B1 (ko) * 2018-10-29 2022-11-16 에프. 호프만-라 로슈 아게 항체 제형
EP3659594B1 (de) * 2018-11-30 2020-11-18 Klaus Stegemann Eine sterile lösung mit einem medizinischen wirkstoff enthaltende applikationsspritze und verfahren für deren bereitstellung
CN118718180A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3150481A1 (en) 2019-09-03 2021-03-11 Amgen Inc. Injection device for drug delivery and packaging for the injection device
JP7704740B2 (ja) 2019-09-16 2025-07-08 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌の方法
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization
JP2022548197A (ja) * 2019-12-06 2022-11-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
EP4196060A1 (en) * 2020-08-12 2023-06-21 Regeneron Pharmaceuticals, Inc. Systems and methods for drug delivery to ocular tissue
WO2022067330A1 (en) * 2020-09-25 2022-03-31 Ocuject, Llc Syringe injector with a feedback mechanism
KR102720956B1 (ko) * 2020-12-15 2024-10-24 삼천당제약주식회사 안과용 제형을 포함하는 시린지

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3380450A (en) * 1965-05-10 1968-04-30 William H. Adelberger Sterile disposable plastic prefilled syringe
US5731144A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US6124449A (en) 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
WO1996038579A1 (en) 1995-06-02 1996-12-05 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to growth factors
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
JP4723140B2 (ja) 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
US7431989B2 (en) 2003-05-06 2008-10-07 Tribofilm Research, Inc. Article with lubricated surface and method
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
MX2010008696A (es) * 2008-02-07 2010-08-30 Amgen Inc Composiciones de proteina estabilizadas.
PT2307454T (pt) 2008-06-25 2017-04-26 Esbatech Alcon Biomed Res Unit Anticorpos estáveis e solúveis que inibem o vegf
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
US9597458B2 (en) * 2009-10-29 2017-03-21 W. L. Gore & Associates, Inc. Fluoropolymer barrier materials for containers
WO2011117878A1 (en) 2010-03-20 2011-09-29 Pawan Trilokchand Agrawal Plastic pre-filled syringe
CN103037802B (zh) * 2010-03-31 2016-08-24 奥库杰克特有限责任公司 用于眼内药物递送的设备和方法
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
DE102011009057B4 (de) * 2011-01-20 2015-12-10 Schott Ag Plasma-Behandlungsvorrichtung zur Herstellung von Beschichtungen und Verfahren zur innenseitigen Plasmabehandlung von Behältern
JP6207401B2 (ja) * 2012-01-31 2017-10-04 テルモ株式会社 プレフィルドシリンジ用シリンジ
PT3858405T (pt) * 2012-06-01 2023-06-26 Novartis Ag Seringa
JOP20200175A1 (ar) * 2012-07-03 2017-06-16 Novartis Ag حقنة
AU2012101678B4 (en) 2012-07-03 2013-01-24 Novartis Ag Use of device
WO2014033184A1 (en) * 2012-08-28 2014-03-06 Novartis Ag Use of a vegf antagonist in treating ocular vascular proliferative diseases
DE102013103676A1 (de) * 2013-04-11 2014-10-30 Schott Ag Behälter mit geringer Partikelemission und reibkontrollierter Trockengleitoberfläche, sowie Verfahren zu dessen Herstellung
CN105377891A (zh) * 2013-07-11 2016-03-02 诺华股份有限公司 Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用
AU2014332236B2 (en) * 2013-10-07 2020-03-05 Ocuject, Llc Intraocular delivery devices and methods therefor
AU2015326037A1 (en) * 2014-10-02 2017-04-13 Terumo Kabushiki Kaisha Medical container for accommodating protein solution preparation therein

Similar Documents

Publication Publication Date Title
JP2019501687A5 (enExample)
RU2018121813A (ru) Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
RU2016148324A (ru) Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
TWI632920B (zh) 注射器
JP6396565B2 (ja) 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
DK2521536T3 (en) STABILIZED FORMULATIONS CONTAINING ANTI-INTERLEUKIN-6 RECEPTOR (IL-6R) ANTIBODIES
TW201726194A (zh) 用於移除帽蓋的系統（二）
CN107001457A (zh) 用于治疗血管性眼病的方法和制剂
JP2014087678A5 (enExample)
JP2019510078A5 (enExample)
JP7695887B2 (ja) 抗ｉｌ－３３抗体を含有する安定化製剤
KR102373289B1 (ko) 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도
KR20230135012A (ko) 혈관형성 눈 장애의 치료를 위한 연장된 고 용량 vegf 길항제 용법
TWI856388B (zh) 含有抗-介白素-4受體(il-4r)抗體之安定化配製物
EP3145532A1 (en) Individualized treatment of eye disease
Kim et al. Differences in the incidence of aflibercept-related sterile endophthalmitis according to types of disposable syringes used
EP3202393B1 (en) Intradermal administration of immunoglobulin g preparation
Hsia et al. Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
Forte et al. Retinal Vein Occlusion Following Two Doses of mRNA-1237 (Moderna) Immunization for SARS-Cov-2: A Case Report
HK40030912A (en) Syringe
Bosnar RANIBIZUMAB FOR NAMD: NEW EVIDENCE TO IMPROVE PATIENT CARE.
Cankaya Acinetobacter baumannii endophthalmitis following intravitreal administration in an elderly patient: case report
Awwad et al. In vitro evaluation of the therapeutic tail of bevacizumab in the eye
HK1232793A1 (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies